Clinical Trial Update: Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy trial of Seqirus A/H7N9 inactivated influenza vaccine with or without MF59 adjuvant for avian influenza prevention completed; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Avian Influenza
• Influenza Immunisation

Drugs mentioned

• MF59(R) adjuvant (MF59 adjuvant)
• Seqirus A/H7N9 IIV (inactivated influenza vaccine targeting A/H7N9)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Avian Influenza, Influenza Immunisation | Phase 2 | Status: COMPLETED | Results posted: 2021-05-17